Patents by Inventor Nicholas Charles Ray
Nicholas Charles Ray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230159511Abstract: The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.Type: ApplicationFiled: April 22, 2021Publication date: May 25, 2023Inventors: Cathy Louise Lucas, Emma Louise Blaney, Barrie Phillip Martin, Thorsten Nowak, Nicholas Charles Ray, Simon Ross Crumpler, Eileen Mary Seward, George Hynd
-
Publication number: 20230045776Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: February 25, 2021Publication date: February 9, 2023Applicant: Genentech, Inc.Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
-
Publication number: 20210236473Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: February 25, 2021Publication date: August 5, 2021Applicant: Genentech, Inc.Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
-
Patent number: 10966963Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: April 17, 2018Date of Patent: April 6, 2021Assignee: Genentech, Inc.Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li, Tommy Lai, Jiangpeng Liao, Zhiguo Liu, John Wai, Tao Wang
-
Patent number: 10654867Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: September 9, 2019Date of Patent: May 19, 2020Assignee: Genentech, Inc.Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Jiangpeng Liao
-
Publication number: 20200002353Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: September 9, 2019Publication date: January 2, 2020Applicant: Genentech, Inc.Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Jiangpeng Liao
-
Publication number: 20190337946Abstract: Triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.Type: ApplicationFiled: July 18, 2019Publication date: November 7, 2019Applicant: Genentech, Inc.Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
-
Publication number: 20190322661Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.Type: ApplicationFiled: June 11, 2019Publication date: October 24, 2019Applicant: Genentech, Inc.Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-wai Yuen
-
Patent number: 10435396Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: GrantFiled: February 28, 2017Date of Patent: October 8, 2019Assignee: Bayer Pharma AktiegesellschaftInventors: Ulrich Bothe, Holger Siebeneicher, Nicole Schmidt, Judith Günther, Holger Steuber, Ulf Bömer, Martin Lange, Reinhard Nubbemeyer, Nicholas Charles Ray, Pascal Savy
-
Publication number: 20190152970Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: January 17, 2019Publication date: May 23, 2019Applicant: Genentech, Inc.Inventors: Sharada LABADIE, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Zhiguo Liu, Tao Wang
-
Publication number: 20190071432Abstract: The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.Type: ApplicationFiled: February 28, 2017Publication date: March 7, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Ulrich BOTHE, Holger SIEBENEICHER, Nicole SCHMIDT, Judith GÜNTHER, Holger STEUBER, Ulf BÖMER, Martin LANGE, Reinhard NUBBEMEYER, Nicholas Charles RAY, Pascal SAVY
-
Publication number: 20180327402Abstract: Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.Type: ApplicationFiled: May 9, 2018Publication date: November 15, 2018Applicant: Genentech, Inc.Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
-
Publication number: 20180305355Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.Type: ApplicationFiled: November 22, 2017Publication date: October 25, 2018Applicant: Genentech, Inc.Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-wai Yuen
-
Publication number: 20180235945Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: April 17, 2018Publication date: August 23, 2018Applicant: Genentech, Inc.Inventors: SHARADA LABADIE, JUN LIANG, DANIEL FRED ORTWINE, XIAOJING WANG, JASON ZBIEG, BIRONG ZHANG, SIMON CHARLES GOODACRE, NICHOLAS CHARLES RAY, JUN LI, TOMMY LAI, JIANGPENG LIAO, ZHIGUO LIU, JOHN WAI, TAO WANG
-
Patent number: 10053451Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: May 25, 2016Date of Patent: August 21, 2018Assignee: Genentech, Inc.Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Birong Zhang, Nicholas D. Smith, Steven P. Govek, Mehmet Kahraman, Andiliy G. Lai, Johnny Y. Nagasawa, Simon Charles Goodacre, Nicholas Charles Ray
-
Patent number: 9980947Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: December 17, 2015Date of Patent: May 29, 2018Assignee: Genentech, Inc.Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li
-
Publication number: 20180086757Abstract: Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3, R4 and R5 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by a JAK kinase in a patient.Type: ApplicationFiled: August 31, 2017Publication date: March 29, 2018Applicant: Genentech, Inc.Inventors: Simon Charles Goodacre, Nicholas Charles Ray, Mark Edward Zak, Yun-Xing Cheng, Wei Li
-
Publication number: 20180002344Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: June 15, 2017Publication date: January 4, 2018Applicant: Genentech, Inc.Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Jiangpeng Liao
-
Publication number: 20170362228Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: June 15, 2017Publication date: December 21, 2017Applicant: Genentech, Inc.Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Zhiguo Liu, Tao Wang
-
Patent number: 9845291Abstract: Described herein are compounds that are estrogen receptor modulators of Formula (I): and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: December 17, 2015Date of Patent: December 19, 2017Assignee: Genentech, Inc.Inventors: Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Steven P. Govek, Mehmet Kahraman, Johnny Y. Nagasawa, Nicholas D. Smith, Simon Charles Goodacre, Nicholas Charles Ray